Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults 18 and older who are patients at the Albany Medical Center Internal Medicine and Pediatrics practice (study site).~2. Clinical diagnosis of acute bacterial sinusitis in accordance with the guidelines of the Infectious Disease Society of America (fitting into one of 3 categories: persistent sinus symptoms for 10 days or more; severe sinus symptoms for 3 days or more; or worsening sinus symptoms after initial improvement (double sickening).~Exclusion Criteria:~1. Previous enrollment in the current study~2. Allergy or intolerance to any penicillin or to amoxicillin/clavulanate~3. Serious hypersensitivity reaction to any beta lactam~4. Elevated risk of amoxicillin-resistant bacteria: a. amoxicillin, penicillin, or other beta-lactam within the past month; b. known to have had methicillin-resistant Staph aureus~5. Chronic or recurrent sinus problems (defined as a) persistent symptoms of sinus congestion, not attributed to nasal allergies, for 8 weeks or more or b) 2 or more episodes of antibiotic-treated sinusitis in past 3 months~6. Need to use high-dose amoxicillin/clavulanate or levofloxacin or to send to emergency department or to hospitalize because of a) signs of severe infection or b) immunocompromise~7. Cognitive impairment, so unable to give reliable symptom ratings (even if a health proxy can give consent)~8. Pregnant women and nursing mothers~9. Drug warnings: a) taking allopurinol; b) current mononucleosis; c) chronic kidney disease stage 4 (estimated glomerular filtration rate \<30); d) hepatic impairment (not including isolated transaminase elevated \< 2 times upper limit of normal); e) history of antibiotic-associated colitis (C. difficile)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose (Type: EXPERIMENTAL): Amoxicillin/clavulanate 875mg/125mg \& amoxicillin 875 mg twice a day x 7 days
- Standard dose (Type: ACTIVE_COMPARATOR): Amoxicillin/clavulanate 875 mg/125mg \& placebo (lactase) twice a day x 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).